The Extrahepatic Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Extrahepatic Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Extrahepatic Bile Duct Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Extrahepatic Bile Duct Cancer and features dormant and discontinued products.

GlobalData tracks 43 drugs in development for Extrahepatic Bile Duct Cancer by 41 companies/universities/institutes. The top development phase for Extrahepatic Bile Duct Cancer is phase ii with 25 drugs in that stage. The Extrahepatic Bile Duct Cancer pipeline has 42 drugs in development by companies and one by universities/ institutes. Some of the companies in the Extrahepatic Bile Duct Cancer pipeline products market are: Chia Tai Tianqing Pharmaceutical Group, Merck and Les Laboratoires Servier.

The key targets in the Extrahepatic Bile Duct Cancer pipeline products market include Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1).

The key mechanisms of action in the Extrahepatic Bile Duct Cancer pipeline product include Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Inhibitor with five drugs in Phase III. The Extrahepatic Bile Duct Cancer pipeline products include 13 routes of administration with the top ROA being Intravenous and seven key molecule types in the Extrahepatic Bile Duct Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.

Extrahepatic Bile Duct Cancer overview

Extrahepatic bile duct cancer is a rare type of cancer that affects the ducts that carry bile from the liver or gallbladder to the small intestine. Bile is a fluid that helps digest fats and remove waste products from the body. Extrahepatic bile duct cancer can block the flow of bile, causing jaundice, itching, abdominal pain, weight loss, and other symptoms. The most common type of extrahepatic bile duct cancer is adenocarcinoma, which starts in the cells that line the ducts. The treatment and prognosis of extrahepatic bile duct cancer depend on the location and stage of the tumor, as well as the patient’s overall health and preferences.

For a complete picture of Extrahepatic Bile Duct Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.